SCHEMBL7677714

SCHEMBL7677714

COc1cc2c(c(C(=O)Cl)c1)CCCC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR5 P32302 1/20 0.42
▸ FLT3 P36888 2/20 0.39
▸ KIT P10721 1/20 0.39
▸ PDGFRA P16234 1/20 0.39
▸ FLT4 P35916 1/20 0.39
▸ KDR P35968 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.38
▸ MAPT P10636 3/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ NPC1 O15118 4/20 0.35
▸ RAB9A P51151 4/20 0.35
▸ POLB P06746 1/20 0.35
▸ NLRP3 Q96P20 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ CASP3 P42574 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7681591 0.85 CXCR5 (0.48) CXCR5HSD17B10MAPTKDM4EPOLB
SCHEMBL7678090 0.84 CXCR5 (0.44) CXCR5HSD17B10MAPTKDM4ENPC1
SCHEMBL7676393 0.83 ALDH1A1 (0.41) CXCR5HSD17B10KDM4ENPC1RAB9A
SCHEMBL9838900 0.73 ALDH1A1 (0.40) MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL30550463 0.72 ALDH1A1 (0.39) MEN1KMT2AALDH1A1
SCHEMBL2999364 0.72 ALDH1A1 (0.39) MEN1KMT2AALDH1A1
SCHEMBL7681848 0.71 MEN1 (0.41) HSD17B10MAPTKDM4EPOLBMEN1
SCHEMBL4266407 0.71 XDH (0.47) CXCR5MAPTKDM4ENPC1RAB9A
SCHEMBL10646843 0.71 NQO2 (0.46) CXCR5MAPTKDM4ETSHRNFKB1
SCHEMBL21357843 0.70 CYP3A4 (0.47) FLT3KITPDGFRAFLT4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6403601-B1 TREATMENT OF ASTHMA, ANXIETY, DEPRESSION, EMESIS, URINARY INCONTINENCE AND RELATED CONDITIONS. ASTRAZENECA AB (SE) 2002-06-11 — — US disclosed
EP-1137637-A1 N-(2-PHENYL-4-PIPERIDINYLBUTYL)-5,6,7,8-TETRAHYDRO-1-NAPHTHALENECARBOXAMIDES AND THEIR USE AS NEUROKININ 1 (NK1) AND/OR NEUROKININ 2 (NK2) RECEPTOR ANTAGONISTS AstraZeneca AB (SE) 2001-10-04 — — EP disclosed
WO-2000034243-A1 N-(2-PHENYL-4-PIPERIDINYBUTYL)-5,6,7,8-TETRAHYDRO-1-NAPHTHALENECARBOXAMIDES AND THEIR USE AS NEUROKININ 1 (NK1) AND/OR NEUROKININ 2 (NK2) RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2000-06-15 — — WO disclosed
Send feedback